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In the past two decades, we and others have 
estimated that more than half of cancers could 
have been prevented by applying knowledge that 
we already have. Tobacco use, inactivity, and 
obesity are modifiable causes of cancer,1-3 and 
evidence now suggests that vaccination against 
the human papillomavirus, the use of aspirin 
and selective estrogen-receptor modulators, and 
participation in screening programs further re-
duce the risk of specific cancers.4,5 The effect of 
these strategies on cancer-related outcomes in 
the general population is significant. A 62% re-
duction in lung-cancer mortality is associated 
with smoking cessation at age 50,6 and environ-
mental and policy strategies are effective at in-
creasing cessation.6-8 A 95% reduction in mortal-
ity is associated with screening for cervical 
cancer,9 a 100% reduction in mortality is associ-
ated with vaccination against the human papil-
lomavirus,10-12 and a 90% reduction in mortality 
related to chronic liver disease and liver cancer 
is associated with vaccination against hepatitis B 
virus.13 There is also benefit for those at high 
risk for cancer. Lung-cancer screening is associ-
ated with a 20% reduction in mortality among 
smokers at high risk, salpingo-oophorectomy 
reduces the risk of breast and ovarian cancer 
among women with a BRCA1/2 mutation,14,15 and 
treatment with selective estrogen receptor mod-
ulators reduces the incidence of breast cancer by 
50% among women at high risk.16,17 Screening, 
diagnosis, and treatment of hepatitis C virus 
infection reduces the risk of all-cause mortality 
by 50% among those with infection.18 Our abil-
ity to prevent cancer has improved significantly.
How Well Do We Use the Evidence 
on C ancer Prevention?
The evidence on cancer prevention has not been 
adopted in the United States as effectively as it 
might have been (Table 1). Among the strategies 
for the prevention of cancer, smoking cessation 
has the longest-standing evidence base. Environ-
mental and policy approaches (e.g,. taxation and 
restrictive policies) that reduce the rate of risky 
behaviors and that increase access to treatment 
are particularly important for tobacco control at 
the population level.6-8,26 However, the current 
federal excise tax on tobacco, $1.01, is low as 
compared with the average of about $3.15 per 
pack in high-income countries worldwide. There 
is often statistically significant variation among 
the states in the implementation of the evidence 
base. One example is state tobacco taxes, which 
range from 17 cents to $4.35 per pack of ciga-
rettes.27 Raising cigarette excise taxes at the 
state and federal levels is viewed as a key strat-
egy in reducing smoking prevalence, yet almost 
one third of states have not raised their taxes in 
10 years. Long-standing gaps in access to cessa-
tion treatment were addressed in the Affordable 
Care Act (ACA),28,29 which is now at risk.
Similar gaps in the implementation of the 
evidence base can be seen in nearly all known 
cancer-prevention strategies. Simply put, as a 
nation, we continue to underinvest in primary 
prevention and screening and fail to adopt strat-
egies to ensure that all population groups ben-
efit equally from our knowledge of cancer pre-
vention. As a result, cancer morbidity and 
mortality are unnecessarily high,30 and these 
high rates translate into huge health care costs 
and a devastating burden for patients and their 
families.31,32 Prevention is much less expensive. 
For example, the economic cost of smoking is 
estimated at $300 billion a year.33 Every $1 ex-
pended on a comprehensive smoking-cessation 
program in Massachusetts was associated with a 
return on investment of $2.12.34
How C an We Ma ximize the Use  
of Existing Evidence?
If we wish to increase the use of the existing 
evidence on cancer prevention, it is imperative 
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that we conduct more dissemination research 
and implementation research focused on cancer 
prevention. Dissemination research is the sys-
tematic study of processes and factors that lead 
to the widespread use of an evidence-based prac-
tice.35 Implementation research focuses on under-
standing the processes and factors that are 
associated with the successful integration of 
evidence-based practices in a particular setting 
(e.g., a primary care clinic or school) and on 
evaluating the effects of any adaptations of the 
practices that are needed in that setting. Togeth-
er, these two approaches, supported by strong 
and growing methods, can help us bend the 
curve on the use of evidence on cancer preven-
tion. Dissemination and implementation research 
focused on the strategies needed to enhance 
population-level cancer prevention may be par-
ticularly productive.26
Environmental and policy initiatives can reach 
a large number of people efficiently.6-8 Dissemi-
nation and implementation research can help to 
elucidate organizational factors that may speed 
implementation differentially across settings. For 
example, worksite smoking bans and compre-
hensive smoking-cessation programs have been 
effective strategies for reducing smoking among 
adults,7 and the organizational characteristics 
associated with the adoption of smoking bans 








Adult 15.1 (2014) West Virginia, 26.7 Utah, 9.7 Data on national prevalence19 and 
statewide prevalence20 are from 
the CDC.
Youth 10.8 (2014) West Virginia, 18.8 Utah, 4.4 All data are from the CDC.21
BMI ≥30† 29.8 (2014) Louisiana, 36.2 Colorado, 20.2 Data are from the CDC.22
Lack of physical  
activity‡
22.1 (2014) Mississippi, 31.4 Colorado, 16.4 Data are from the CDC.22
Fruit intake (≥2 cups/day) 13.1 (2013) California, 17.7 Tennessee, 7.5 Data are from Moore and 
Thompson.23
Vegetable intake (2.5–3 
cups/day
8.9 (2013) California, 13.0 Mississippi, 5.5 Data are from Moore and 
Thompson.23
Screening for colon  
cancer§
66.4 (2014) Massachusetts, 76.5 Wyoming, 56.9 Data are from the CDC.20
Mammography¶ 73.0 (2014) Massachusetts, 82.1 Idaho, 62.5 Data are from the CDC.20
Pap test‖ 82.6 (2014) Massachusetts, 88.0 Idaho, 76.2 Data are from the CDC.20








Mississippi, 24.4  
Boys: 
Tennessee, 16.0
Data are from Reagan-Steiner et al.24
HBV vaccination†† 72.4 (2014) North Dakota, 88.4 Vermont, 48.4 Data are from Hill et al.25
*  CDC denotes Centers for Disease Control and Prevention.
†  BMI denotes body-mass index, calculated as the weight in kilograms divided by the square of the height in meters. Some organizations 
now classify obesity as a BMI of 30 or higher.
‡  The lack of physical activity is defined as no leisure-time physical activity among persons 18 years of age or older.
§  The percentages for colon-cancer screening are based on persons between 50 and 75 years of age for whom the screening met the recom-
mendations of the U.S. Preventive Services Task Force.
¶  Data on mammography are from women 40 years of age or older who had a mammogram within the preceding 2 years.
‖  Data on the Papanicolaou (Pap) test are from women 21 to 65 years of age who had a Pap test within the preceding 3 years.
**  These children received at least three vaccinations against the human papillomavirus (HPV).
††  Vaccinations against hepatitis B virus (HBV) were administered from birth through the age of 3 days.
Table 1. Prevalence of Factors That Modify the Risk of Cancer in the United States.*
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policy interventions might focus on areas where 
there has been resistance to the adoption of 
evidence-based strategies, such as states with 
low excise taxes or limited implementation of 
restrictive smoking policies, as noted above. Envi-
ronments that provide access to groups with an 
elevated prevalence of risk-related behaviors are 
another important target. For example, higher 
rates of implementation of evidence-based 
 tobacco-control interventions are needed in set-
tings that provide care to people with mental 
health and substance-abuse issues, since the 
prevalence of smoking in these two groups is 
much greater than that in the general popula-
tion.38 Only 35% of substance abuse treatment 
facilities39 have a smoking ban, only about half 
provide any counseling or medication for smok-
ing cessation,40 and psychiatrists deliver cessa-
tion counseling to patients who smoke at only 
12% of visits.41 Despite the demonstrated effi-
cacy of smoking-cessation treatment in the con-
text of mental health care, only 13 states require 
provision of cessation treatment in facilities that 
provide treatment for alcohol abuse, drug abuse, 
or other conditions related to mental health.42 It 
is likely that the facilitators of the adoption of 
antismoking policies are different in treatment 
centers and the workplace. Dissemination and 
implementation research can help to determine 
how to increase the use of smoking bans and the 
provision of comprehensive treatment in these 
settings, as can changes in state and federal 
policy that provide protection from exposure to 
secondhand smoke and ensure access to cessa-
tion treatment.
The setting in which cancer is treated is an-
other important target for increasing the use of 
evidence on cancer prevention. The 2014 Sur-
geon General’s report concludes that there is a 
causal relationship between smoking and ad-
verse health outcomes and mortality among 
people with cancer and that all-cause mortality 
could be lowered in such people by 30 to 40% if 
they would stop smoking at the time of diagno-
sis.7 Reasoning by analogy, a cancer center that 
did not use evidence-based chemotherapy proto-
cols would not be competitive for funding from 
the National Cancer Institute. Applying the same 
expectation for the evidence-based treatment of 
behavioral risk factors among people with known 
cancer could accelerate the reduction in the risk 
of death for the 13 million cancer survivors in 
the United States and thereby benefit not only 
patients but their families and caregivers. Dis-
semination and implementation research should 
focus on improving our understanding of the 
factors at the provider, patient, organizational, 
and policy levels that impede the adoption of 
evidence-based cancer-prevention strategies.
Increased population-level access to cancer 
prevention can also be achieved by focusing re-
search efforts across multiple levels of influence, 
often through new and nontraditional partner-
ships. As the examples above illustrate, there is a 
need for both policies that encourage behaviors 
related to risk reduction and access to evidence-
based treatments. If the ACA is largely repealed, 
access to evidence-based treatment will be re-
duced or eliminated for millions of smokers. 
Access to cancer-screening services will also be 
reduced. Other avenues of access must be creat-
ed. The Center for Medicare and Medicaid Ser-
vices (CMS) could use its innovation awards to 
aid the development of new strategies that would 
provide access to screening services and to ex-
pand the use of evidence-based cancer-preven-
tion strategies, as it has done in helping to re-
duce the risk of cardiovascular disease. It would 
be valuable to determine whether state-level 
efforts lead to outcomes that are different from 
those supported by CMS investment, whether 
CMS resources could be used to advance state-
level efforts to boost the implementation of evi-
dence-based research, and whether partnerships 
with parties whose focus is not health care (e.g., 
schools, churches, and government agencies 
such as agriculture and housing) could help to 
increase use. In collaboration with the National 
Institutes of Health and the Centers for Disease 
Control and Prevention, targeted research oppor-
tunities could be created to maximize the knowl-
edge gained.
Social determinants contribute to disparities in 
cancer morbidity and mortality.43 Organizations 
that serve communities with limited economic 
resources, such as safety-net health centers, have 
a particular role to play in ensuring equitable 
access to cancer-prevention programs. However, 
given limited resources and high demand, it can 
be difficult to integrate new practices into such 
organizations. Initial work suggests that some 
of the characteristics of an organization or com-
munity (e.g., the willingness of leaders to engage, 
tension with regard to change or a perception 
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that the current situation is intolerable, and the 
presence of formally appointed implementation 
leaders), in addition to characteristics of the in-
tervention itself, differentiate systems that adopt 
evidence-based practices from lower-performing 
systems.44,45 Research is needed that incorporates 
the full range of factors that influence imple-
mentation in areas that serve populations with a 
high cancer burden and limited resources.46
Conclusions
If we are to benefit as a nation from our invest-
ment in cancer research, it is imperative that we 
focus on strategies that will reduce the variation 
in the implementation of effective cancer-pre-
vention programs. We have much to learn from 
organizations and communities that make great-
er use of prevention-focused policies, and we 
need to broaden our understanding of the social, 
political, and environmental factors that favor the 
implementation of evidence-based programs.47 If 
our efforts to reduce the cancer burden are to go 
beyond rhetoric, they must address the factors 
involved in implementation that account for dis-
parities in outcome and have the greatest effect 
on populations with the largest cancer burden. 
When we implement evidence-based prevention 
and screening programs correctly and at scale, 
we achieve substantial population benefits. Al-
though many efforts are under way to maximize 
our knowledge about the causes and treatments 
of cancer, we can achieve reductions in the can-
cer burden right now by doing what we already 
know works. Enhanced investment in research 
that increases our understanding of how to im-
plement the knowledge we have is needed. Our 
moonshot is right here — ready for the taking.
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